Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675024 | 0.90 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL17263066 | 0.90 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL22778063 | 0.88 | ACSS2 (0.64) | ACSS2 | |
| SCHEMBL18674923 | 0.88 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL18674927 | 0.86 | ACSS2 (0.77) | ACSS2 | |
| SCHEMBL18675134 | 0.84 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL20457046 | 0.84 | ACSS2 (0.88) | ACSS2 | |
| SCHEMBL18674965 | 0.83 | ACSS2 (1.00) | ACSS2 | |
| SCHEMBL17263143 | 0.82 | ACSS2 (0.74) | ACSS2 | |
| SCHEMBL17267073 | 0.82 | ACSS2 (0.75) | ACSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | ACSS2, GLS2, ACSL3 | ACSS2 1/4885 |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | ACSS2, GLS2, ACSL3 | ACSS2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.